|
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | - | Shs Outstand | 20.70M | Perf Week | -1.76% |
| Market Cap | 259.81M | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 20.70M | Perf Month | -2.51% |
| Income | - | PEG | - | EPS next Q | - | Inst Own | 2.08% | Short Float / Ratio | 0.00% / 0.04 | Perf Quarter | -0.20% |
| Sales | - | P/S | - | EPS this Y | - | Inst Trans | - | Short Interest | 0.00M | Perf Half Y | 0.40% |
| Book/sh | -0.47 | P/B | - | EPS next Y | - | ROA | - | Target Price | - | Perf Year | -1.08% |
| Cash/sh | - | P/C | - | EPS next 5Y | - | ROE | - | 52W Range | 9.90 - 10.58 | Perf YTD | -1.66% |
| Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -4.71% | Beta | - |
| Dividend % | - | Quick Ratio | - | Sales past 5Y | - | Gross Margin | - | 52W Low | 1.82% | ATR | 0.09 |
| Employees | - | Current Ratio | - | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 43.31 | Volatility | 0.00% 0.40% |
| Optionable | No | Debt/Eq | - | EPS Q/Q | - | Profit Margin | - | Rel Volume | 0.01 | Prev Close | 10.27 |
| Shortable | Yes | LT Debt/Eq | - | Earnings | - | Payout | - | Avg Volume | 5.25K | Price | 10.08 |
| Recom | - | SMA20 | -1.21% | SMA50 | -1.59% | SMA200 | -0.43% | Volume | 50 | Change | -1.85% |
 | ||||||||||||||||
| ||||||||||||||||
|
||||||||||||||||
| ||||||||||||||||
| Intelligent Medicine Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. It intends to identify business opportunities in the field of life science. The company was incorporated in 2021 and is based in Bethesda, Maryland. | ||||||||||||||||
| ||||||||||||||||
|
| open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite